"I am expecting a replication of Phase 2 with benefit (increase) in apabetalone group and no benefit (decrease) in placebo group."

Yes - in the CKD patients; there is no reason to expect eGFR to increase in the nonCKD patients since their values were in the normal range (>60) to begin with. This is consistent with a lack of change in the eGFR values for the apabetalone treatment group over the entire trial population.  However, I do expect a decrease in ALP levels in the apabetalone-treated nonCKD group as well as CKD group.  If this is true, there is the possibility that ongoing apabetalone treatment in this patient group may prevent the development of CKD through its ALP-lowering effect that retards or eliminates the process of vascular calcification, as well as through downregulation of other inflammatory and fibrotic processes such as endothelial to mesenchymal transition.

Jupe